Morgan Stanley raised the firm’s price target on Gilead (GILD) to $151 from $147 and keeps an Overweight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead price target raised to $133 from $110 at HSBC
- Assembly Biosciences announces interim results from ABI-1179, ABI-5366 trials
- Mirum’s deal for Bluejay a positive readthrough to Vir, says Needham
- Gilead Sciences’ Strong Market Position and Promising Anito-cel Data Support Buy Rating
- Gilead’s Kite presents new analysis on second-line Yescarta therapy